Release Summary

X4 Pharmaceuticals announced dosing of the first patient in the Phase 2 portion of the ongoing Phase 1/2 study evaluating X4P-001 in patients with advanced clear cell renal cell carcinoma (ccRCC).

X4 Pharmaceuticals